318 results
Page 4 of 16
8-K
EX-99.1
pa8eh9rpku9js
14 Jan 21
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
5:13pm
8-K
EX-4.3
bfbahh429myvi0
14 Jan 21
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
5:13pm
424B4
u2zq32naccx1bv9rqw6n
14 Jan 21
Prospectus supplement with pricing info
12:00am
8-K/A
EX-99.1
3ljh8umltpp
31 Dec 20
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets
1:57pm
8-K
EX-99.1
tpe kkrxhp
22 Dec 20
Regulation FD Disclosure
3:16pm
8-K
EX-99.1
mgqr6daqo43k4amv
10 Dec 20
Lexaria Closes Sale of Non-Pharmaceutical THC-Related Assets
12:19pm
8-K
EX-99.1
uew4k0w
2 Dec 20
Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
1:24pm
8-K
EX-99.1
vxcnae33wq2
19 Nov 20
Entry into a Material Definitive Agreement
4:29pm
DRS
djh8 1xcte
13 Nov 20
Draft registration statement
12:00am
8-K
EX-99.1
9dq72 6v1
6 Nov 20
Lexaria Bioscience Advances 2021 Strategic Initiatives
12:00am
8-K
EX-99.1
03k 0xlmw064ax
16 Jul 20
Altria and Lexaria Conclude Phase I Research and Development Program
11:15am